United Kingdom

People: Constellation Pharmaceuticals Inc (CNST.OQ)

CNST.OQ on NASDAQ Stock Exchange Global Select Market

13 Sep 2019
Change (% chg)

$0.01 (+0.13%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Audia, James 

Dr. James E. Audia, Ph.D., serves as Director of the company since July 2017. Dr. Audia currently serves as Executive Director of the Chicago Biomedical Consortium, or CBC, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation. Prior to joining the CBC in August 2017, Dr. Audia served as our chief scientific officer from January 2011 to July 2017. Prior to joining us as chief scientific officer, Dr. Audia served in a number of roles at Eli Lilly & Company, a global healthcare company, from 1987 until December 2010. From January 2011 to December 2017, Dr. Audia served as a scientific advisor to Sage Therapeutics, Inc., a public biopharmaceutical company. Dr. Audia also serves as a scientific advisor and a member of the board of directors of Ribon Therapeutics, Inc., a private biotechnology company. He received a B.S. and Ph.D. in organic chemistry from the University of South Carolina and completed postdoctoral training at Yale University.

Basic Compensation

Total Annual Compensation, USD 10,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 84,644
Fiscal Year Total, USD 94,644

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --